Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5240216 | 0.87 | KDM4E (0.57) | KCNH2NPSR1CYP1A2BRD4KDM4E | |
| SCHEMBL12432224 | 0.86 | IRAK4 (0.49) | KCNH2NPSR1CYP1A2BRD4ALDH1A1 | |
| SCHEMBL3935225 | 0.85 | MBOAT4 (0.47) | KCNH2CTSSCTSKNPSR1CYP1A2 | |
| Alcohol SCHEMBL4865562 | 0.83 | NPSR1 (0.42) | KCNH2NPSR1CYP1A2BRD4ALDH1A1 | |
| SCHEMBL31013362 | 0.83 | ALDH1A1 (0.46) | KCNH2NPSR1CYP1A2BRD4ALDH1A1 | |
| SCHEMBL1054149 | 0.82 | NPSR1 (0.44) | NPSR1CYP1A2BRD4ALDH1A1KDM4E | |
| SCHEMBL30952862 | 0.82 | NPSR1 (0.44) | NPSR1CYP1A2BRD4ALDH1A1KDM4E | |
| SCHEMBL5269435 | 0.82 | CYP1A2 (0.50) | NPSR1CYP1A2BRD4NPC1RAB9A | |
| SCHEMBL8662483 | 0.81 | KCNH2 (0.43) | KCNH2NPSR1CYP1A2BRD4ALDH1A1 | |
| SCHEMBL9993619 | 0.81 | CYP1A2 (0.72) | NPSR1CYP1A2ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160271137-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | UNIV PRINCETON (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271137-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | UNIV PRINCETON (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9296736-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9168269-B2 | Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9168269-B2 | Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8569341-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130190381-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190381-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012139028-A2 | ANTI-VIRAL COMBINATION THERAPY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011103516-A2 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | KCNH2 4697/4885CTSS 2759/4885CTSK 1837/4885 |
| US-20160271137-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | FASN, PLIN1, PLIN3 | KCNH2 4693/4885CTSS 850/4885CTSK 2044/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | KCNH2 4697/4885CTSS 2759/4885CTSK 1837/4885 |
| US-20130190381-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | FASN, PLIN1, PLIN3 | KCNH2 4693/4885CTSS 850/4885CTSK 2044/4885 |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNH2 4697/4885CTSS 2759/4885CTSK 1837/4885 |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | KCNH2 4697/4885CTSS 2759/4885CTSK 1837/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | KCNH2 4862/4885CTSS 248/4885CTSK 1129/4885 |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNH2 4697/4885CTSS 2759/4885CTSK 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.